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INTRODUCTION
Treatment with pharmacologic doses of glucocorticoids
frequently results in significant osteoporosis (1). Patients on
high-dose glucocorticoid therapy are susceptible to bone loss
and vertebral fractures within weeks to months of initiation
of therapy (2). It is generally accepted that glucocorticoids
decrease bone formation and increase bone resorption in vitro
as well as in vivo (3-5). In contrast to the consistent finding
of reduced osteoblastic activity, the exact mechanism respon-
sible for the effects of glucocorticoids on bone resorption is
less clear. It may involve both direct effects on osteoclasts (4)
as well as indirect effects mediated through osteoblasts (6).
Despite these side effects, glucocorticoids are necessary for
the treatment of a variety of medical diseases. Deflazacort is
a synthetic glucocorticoid with antiinflammatory and anti-
immune properties similar to those reported for prednisone
and has been reported to be relatively bone sparing (7). Al-
though long-term clinical trials comparing deflazacort with
prednisone are not available, an initial study suggests that
trabecular bone loss is less with deflazacort compared to pred-
nisone (8). Deflazacort and other glucocorticoids have simi-
lar inhibitory actions on aspects of bone formation in cultures
of intact calvariae and osteoblast-enriched cells. Information
on precise effects of deflazacort on bone cell function, espe-
cially osteoclasts, is quite limited. Therefore, the present
study was undertaken to compare the effect of deflazacort
and dexamethasone on aspects of osteoclast formation in
mouse marrow culture. Recently osteoprotegerin (OPG) and
its ligand (RANKL) were cloned and demonstrated to be
critical regulators of osteoclastogenesis (9, 10). OPG is a
novel receptor that blocks osteoclast formation. Either in a
cell membrane-bound or in a soluble form, RANKL stimu-
lates osteoclastogenesis and osteoclastic bone resorption.
OPG and RANKL are expressed by marrow stromal cells,
osteoblast-like cell lines and primary cultures of osteoblasts
derived from mouse calvaria. Recent studies demonstrated
that OPG and RANKL gene expressions in osteoblastic cells
are regulated by various calciotropic hormones and cytokines
(11). Furthermore, Hofbauer et al. has identified that glucocor-
ticoids promote osteoclastogenesis by inhibiting OPG and
concurrently stimulating RANKL production by osteoblas-
tic lineage cells, thereby enhancing bone resorption (12).
In order to find out differences of deflazacort in terms of
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Deflazacort Increases Osteoclast Formation in Mouse Bone Marrow
Culture and the Ratio of RANKL/OPG mRNA Expression in Marrow
Stromal Cells
Information on precise effects of deflazacort on bone cell function, especially
osteoclasts, is quite limited. Therefore, the present study was undertaken to test
effects of deflazacort on osteoclast-like cell formation in mouse bone marrow
cultures and on the regulation of osteoprotegerin (OPG) and its ligand (RANKL)
mRNA expressions by RT-PCR in the ST2 marrow stromal cells. TRAP-positive
mononuclear cells increased after the treatment of deflazacort at 10-9 to 10-7 M
alone for 6 days in a dose-dependent manner. Number of TRAP-positive multi-
nucleated cells (MNCs) increased significantly with combined treatment of deflaza-
cort at 10-7 M and 1,25-(OH)2D3 at 10-9 M compared to that of cultures treated
with 1,25-(OH)2D3 alone (p<0.05). Exposure to deflazacort at 10-7 M in the pres-
ence of 1,25-(OH)2D3 at 10-9 M in the last 3-day culture had greater stimulatory
effect on osteoclast-like cell formation than that of the first 3-day culture did. De-
flazacort at 10-10-10-6 M downregulated OPG and upregulated RANKL in mRNA
levels in a dose-dependent manner. These observations suggest that deflaza-
cort stimulate osteoclast precursor in the absence of 1,25-(OH)2D3 and enhance
differentiation of osteoclasts in the presence of 1,25-(OH)2D3. These effects are,
in part, thought to be mediated by the regulation of the expression of OPG and
RANKL mRNA in marrow stromal cells.
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bone effects, we have investigated the effects of deflazacort
on osteoclast-like cell formation in mouse bone marrow cul-
tures, and on OPG and RANKL mRNA expression in ST2
cells.
MATERIALS AND METHODS
Bone marrow culture system
Six- to 9-week-old male ICR mice were sacrificed and bone
marrow was obtained as described by Takahashi et al. (13).
Briefly, tibiae and femora were dissected free of adherent soft
tissues, both epiphyses were cut off with scissors, and the
marrow cavities were vigorously flushed out with  -mini-
mum essential medium ( -MEM, Gibco BRL, Grand Island,
NY, U.S.A.) using a syringe. Freshly isolated whole bone
marrow cells were cultured in  -MEM containing 10% fetal
calf serum (FCS, Gibco BRL) at 1.5×106 cells/mL in 48-well
plates (Nunc, Denmark). Cultures were fed every 3 days by
replacing half of the media. 10-9 M of 1,25-(OH)2D3 (Cal-
biochem, U.S.A.) and various concentrations of deflazacort
(Gruppo Lepetit, Italy) were added at the beginning of the
culture and at each media change. All cultures were main-
tained at 37℃ in a humidified atmosphere of 5% CO2 and
95% air. After various periods of culture, cells were fixed with
citrate-acetone-formaldehyde fixative, and stained for TRAP
using an acid phosphatase kit (Sigma). TRAP-positive cells
containing three or more nuclei were scored as osteoclasts
microscopically. The results were expressed as the mean±
SEM for four cultures.
Semiquantitative RT-PCR
Osteoclast formation-supporting stromal cell line, ST2
cells (RIKEN cell bank, Tsukuba, Japan) were cultured in
6-well plates containing  -MEM supplemented with 10%
heat-inactivated fetal calf serum (FCS) at 37℃ in a humidi-
fied atmosphere of 5% CO2 and 95% air. When the effect
of deflazacort was to be tested, ST2 cells were serum-starved
in  -MEM containing 0.5% FCS for a period of 24 hr, fol-
lowed by the addition of deflazacort at final concentrations
ranging from 10-10 to 10-6 M. Total RNA was extracted from
the ST2 cells with Tri-reagent (Molecular Research Center,
Cincinnati, OH, U.S.A.) and then used for reverse transcrip-
tase PCR (RT-PCR) assay. PCR reactions were done using
gene-specific PCR primers and Taq polymerase (SR producs,
U.K.) in a thermal cycler (Perkin-Elmer Corp., Norwalk,
CT, U.S.A.). Specific primer sets were designed from pub-
lished cDNA sequences: murine OPG (sense: 5
、 -AACCCC
AGAGCGAAACAC-3
、 ; antisense: 5
、 -AAGAAGGCCTCT
TCACAC-3
、 ), murine RANKL (sense: 5
、 -GGTCGGGCA
ATTCTGAATT-3
、 ; antisense: 5
、 -GGGGAATTACAAAG
TGCACCAG-3
、 ), -actin (sense: 5
、 -GTGGGCCGCCCT
AGGCACCAG-3
、 ; antisense: 5
、 -CACTTTGATGTCACG
CACGATTTC-3
、 ). The amplified samples were run on a 1.5-
2.0% agarose gel, stained with ethidium bromide, and photo-
graphed under UV illumination. Optical density was deter-
mined using a digital image processing and analysis program
(Vilber Lourmate, France). Ratios of OPG or RANKL/- actin
PCR product density were determined for semiquantitation
of mRNA expression. The conditions for the PCR reaction
for mouse OPG cDNA of 219 bp was 95℃ for 50 sec, 54℃
for 20 sec, and 72℃ for 20 sec for 35 cycles. The conditions
for PCR analysis of RANKL were the same as for OPG except
an annealing temperature of 62℃. PCR was performed for
27 cycles for  -actin.
Statistical analysis
Statistical analysis was performed using Student’ s t-test to
evaluate differences between the sample of interest and its
respective control. For analysis of dose response, multiple
measurement ANOVA was used. A p value of <0.05 was
considered significant.
RESULTS
Effects of glucocorticoids on the formation of osteo-
clast-like cells
TRAP-positive multinucleated cells (MNCs) did not in-
crease in cultures treated with deflazacort alone, whereas
TRAP-positive mononuclear cells increased (data not shown).
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Fig. 1. Effects of increased concentration of glucocorticoids on
the formation of TRAP-positive multinucleated cells. TRAP-posi-
tive cells were counted after mouse marrow culture in the pres-
ence of 1,25-(OH)2D3, 10-9 M for 6 days. Data are expressed as
the mean±SEM for four cultures (*: p<0.05).
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Fig. 1 shows the effects of increased concentration of gluco-
corticoids on the formation of TRAP-positive MNCs in the
presence of 1,25-(OH)2D3 (10-9 M) for 6 days. The addition
of dexamethasone or deflazacort to the cultures resulted in
enhancement of TRAP-positive MNC formation induced by
1,25-(OH)2D3. A significant increase was observed at the
concentration of 10-7M dexamethasone or deflazacort (p<
0.05). To characterize the time course for the effects of gluco-
corticoids on osteoclast formation, mouse bone marrow cul-
tures were treated with dexamethasone or deflazacort for vary-
ing time. The number of TRAP-positive MNCs by 10-9 M
1,25-(OH)2D3 and 10-7 M glucocorticoids reached a nearly
maximal level with treatment of dexamethasone or deflaza-
cort in the last 3 days of culture (Fig. 2).
Regulation of OPG and RANKL mRNA expression by
deflazacort in ST2 cell
OPG, RANKL, and  -actin mRNA expression levels were
assessed by RT-PCR in ST2 cell cultures that were treated
with or without deflazacort for 8 hr. The amounts of OPG and
RANKL mRNA were compared with the amount of  -actin
mRNA. As shown in Fig. 3, the level of OPG mRNA expres-
sion decreased significantly after treatment with deflazacort
at and above the concentration of 10-7 M. On the contrary,
stimulation with deflazacort for 8 hr increased the RANKL
mRNA levels in a dose-dependent manner (Fig. 4).
DISCUSSION
Deflazacort has a similar effect on osteoclast formation com-
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Fig. 2. Effects of varying treatment time with glucocorticoids on
the TRAP-positive multinucleated cells in mouse bone marrow
cultures in the presence of 1,25-(OH)2D3, 10-9 M for 6 days. During
the indicated times, cells were cultured with 10-7 M of glucocor-
ticoids (*: p<0.05).
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Fig. 3. mRNA expression of OPG and -actin assessed by RT-
PCR in ST2 cells. ST2 cells were precultured and then stimulat-
ed, with or without deflazacort, for 8 hr. (A) Photographs of the
PCR analysis from a representative experiment. (B) Mean optical
density ratio values for OPG, normalized to  -actin of triplicate
independent experiments, to document the consistency of the
results (*: p<0.01).
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Fig. 4. mRNA expression of RANKL and -actin assessed by RT-
PCR in ST2 cells. ST2 cells were precultured and then stimulat-
ed, with or without deflazacort, for 8 hr. (A) Photographs of the
PCR analysis from a representative experiment. (B) Mean optical
density ratio values for RANKL, normalized to  -actin of triplicate
independent experiments, to document the consistency of the
results (*: p<0.01).
Deflazacort (M)
-actin
RANKL
A
B
* *
* *
*772 H. Chung, Y.S. Kang, C.S. Hwang, et al.
pared with those of dexamethasone (14). No differences in
osteoclast formation of deflazacort and dexamethasone were
detected in this study (Fig. 1). The number of TRAP-posi-
tive mononuclear cells was also increased by treatment with
deflazacort alone, suggesting that deflazacort may induce
proliferation or differentiation of osteoclast precursors in
mouse bone marrow cultures. Time-course effect for TRAP-
positive MNC formation showed that deflazacort had its
greatest stimulatory effects on osteoclast formation during
the later stages of the cultures, the period of differentiation,
rather than during the proliferation phase of mouse bone
marrow cultures (Fig. 2). Although it is possible that deflaza-
cort stimulated osteoclast-like cell formation by directly act-
ing on hematopoietic cells, based on our results, it is more
likely that deflazacort mediates its effects through stromal
cells in enhancing osteoclast formation in mouse bone mar-
row cultures. Most of the TRAP-positive mononuclear cells
and MNCs were found adjacent to colonies of osteoblast-like
cells stained for alkaline phosphatase. Alkaline phosphatase
positive cells appeared almost on day 3 (13).
The balance between osteoblast and osteoclast functions
is regulated systemically by a variety of hormones and locally
by the production of paracrine factors by osteoblasts or bone
marrow stromal cells that regulate osteoclast function (15,
16). The development of active osteoclasts in vitro requires
intimate contact between osteoblastic stromal cells and osteo-
clast precursors (17). RANKL, receptor activator of NF-kappa
B (RANK), and OPG have recently been identified as ago-
nist, receptor, and decoy receptor for osteoclastogenesis. Fac-
tors that stimulate bone resorption increase RANKL expres-
sion and, with some exceptions, decrease OPG expression
(11, 18). In the present study, although we did not evaluate
protein expressions, deflazacort treatment on mouse marrow
stromal cells inhibited the production of OPG and increased
RANKL in mRNA levels (Fig. 3, 4). No differences on OPG
and RANKL mRNA regulation of deflazacort and dexa-
methasone were detected in this semiquantitative RT-PCR
(data not shown). This differential regulation of OPG and
RANKL by deflazacort would favor the formation of osteo-
clasts. These findings are in line with a study that showed
dexamethasone promotes osteoclastogenesis by inhibiting
OPG and stimulating RANKL production by osteoblastic
lineage cells (12). We can not explain the bone-sparing effect
of deflazacort in terms of osteoclast formation based on our
study. Glucocorticoids, including deflazacort, affect multi-
ple parameters of mineral metabolism (19-21). All these
studies assumed that the potency of prednisone relative to
deflazacort was 1.2. Subsequent re-examination of the rela-
tive potencies of these two glucocorticoids has found that
the true relative potency is 1.4-1.8 (22). This study suggest
that deflazacort have been overestimated in the past, and
demonstrated no bone sparing effect when used in a thera-
peutically equivalent dose.
In conclusion, as in other glucocorticoids, deflazacort also
has  stimulatory effects on osteoclast formation, and displays
similar differential regulation of the expression of genes re-
sponsible for osteoclastogenesis in marrow stromal cells.
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